Annual report pursuant to Section 13 and 15(d)


Cover - USD ($)
12 Months Ended
Dec. 31, 2023
Mar. 08, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Amendment Description Corbus Pharmaceuticals Holdings, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment No. 1”) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Original Form 10-K”), filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2024, only for the purpose of amending and restating Item 11 of Part III of the Original Form 10-K to include certain information which was inadvertently omitted in the Original Form 10-K.In addition, pursuant to SEC rules, Item 15 of Part IV of the Original Form 10-K is hereby amended solely to include, as Exhibits 31.1 and 31.2, new certifications of our principal executive officer and principal financial officer pursuant to Rule 13a-14(a) under the Exchange Act of 1934 (the “Exchange Act”). Because no financial statements are included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of such certifications have been omitted. We are not including new certifications required by Rule 13a-14(b) under the Exchange Act as no financial statements are included in this Amendment No. 1.Except for the changes to Item 11 of Part III and the filing of related certifications added to the list of Exhibits in Item 15 of Part IV, this Amendment No. 1 makes no changes to the Original Form 10-K.In addition, no other information has been updated for any subsequent events occurring after March 12, 2024, the date of the filing of the Original Form 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-K and our other filings made with the SEC subsequent to the filing of the Original Form 10-K. Unless the context otherwise requires, references in this Amendment No. 1 to “Corbus,” the “Company,” “we,” “us,” or “our” mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates.    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 001-37348    
Entity Registrant Name Corbus Pharmaceuticals Holdings, Inc.    
Entity Central Index Key 0001595097    
Entity Tax Identification Number 46-4348039    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 500 River Ridge Drive    
Entity Address, City or Town Norwood    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02062    
City Area Code 617    
Local Phone Number 963-0100    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol CRBP    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 34,571,068
Entity Common Stock, Shares Outstanding   10,493,108  
ICFR Auditor Attestation Flag false    
Documents Incorporated by Reference


Auditor Firm ID 274    
Auditor Location Iselin, New Jersey    
Auditor Name EisnerAmper LLP